Orion signs $16 million deal with Jemincare for development of novel non-opioid pain treatment

May 13, 2022

Pfizer EU Tafamidis Patent Withdrawal

February 12, 2026

IntraBio Plans Regulatory Submissions for Aqneursa in Ataxia-Telangiectasia Following Phase 3 Results

January 28, 2026

Must Read

Top 10 Technologies Accelerating Drug Discovery

August 9, 2026

FDA Advisory Panel to Review Grail’s Galleri Multi-Cancer Blood Test in September

August 9, 2026

Actimed Reclaims Rights to Wasting Disease Drug; $126M Faraday Deal Dead

August 9, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Merck’s Tulisokibart Misses Phase 2 Endpoint in SSc-ILD but Meets Goals in HS Trial

After phase 3 data ended blockbuster hopes, GSK eliminated a major cough medication candidate

Hansoh Announces Fresh Phase 3 Victory For Priority ADC

Altimmune Reports Phase 2 Pemvidutide Results in Alcohol Use Disorder

Actimed Reclaims Rights to Wasting Disease Drug; $126M Faraday Deal Dead

The biggest pharmaceutical deal ever would be the “unlikely” AstraZeneca-BMS mega-merger

Supernus and Indivior Agree to Create CNS-Focused Company in All-Stock Merger

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

Top 10 Technologies Accelerating Drug Discovery

What an Autonomous Clinical Trial Might Look Like by 2030

From Data-Rich to Insight-Rich: Pharma’s Next Transformation

The New Competitive Advantage in Biopharma Isn’t Science Alone

Tag: Actimed drug

Actimed Reclaims Rights to Wasting Disease Drug; $126M Faraday Deal Dead

Editor Picks

Orion signs $16 million deal with Jemincare for development of novel non-opioid pain treatment

Pfizer EU Tafamidis Patent Withdrawal

IntraBio Plans Regulatory Submissions for Aqneursa in Ataxia-Telangiectasia Following Phase 3 Results

Must Read

Top 10 Technologies Accelerating Drug Discovery

FDA Advisory Panel to Review Grail’s Galleri Multi-Cancer Blood Test in September

Actimed Reclaims Rights to Wasting Disease Drug; $126M Faraday Deal Dead

Hot Topics

About Us

Follow Us